Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||
| DOI | 10.1093/INFDIS/JIAD320 | ||
| Año | 2023 | ||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Background: We sought to identify potential antigens for discerning between humoral responses elicited after vaccination with CoronaVac (a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] inactivated vaccine), natural infection, or breakthrough infection. Methods: Serum samples obtained from volunteers immunized with CoronaVac (2 and 3 doses), breakthrough case patients, and from convalescent individuals were analyzed to determine the immunoglobulin (Ig) G responses against 3 structural and 8 nonstructural SARS-CoV-2 antigens. Results: Immunization with CoronaVac induced higher levels of antibodies against the viral membrane (M) protein compared with convalescent subjects both after primary vaccination and after a booster dose. Individuals receiving a booster dose displayed equivalent levels of IgG antibodies against the nucleocapsid (N) protein, similar to convalescent subjects. Breakthrough case patients produced the highest antibody levels against the N and M proteins. Antibodies against nonstructural viral proteins were present in >50% of the convalescent subjects. Conclusions: Vaccinated individuals elicited a different humoral response compared to convalescent subjects. The analysis of particular SARS-CoV-2 antigens could be used as biomarkers for determining infection in subjects previously vaccinated with CoronaVac.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Duarte, Luisa F. | Mujer |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile Universidad Nacional Andrés Bello - Chile |
| 2 | Vazquez, Yaneisi | - |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile |
| 3 | Diethelm-Varela, Benjamin | - |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile |
| 4 | Pavez, Valentina | - |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile |
| 5 | Berrios-Rojas, Roslye | - |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile |
| 6 | Mendez, Constanza | - |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile |
| 7 | RIEDEL-SORIA, CLAUDIA ANDREA | Mujer |
Instituto Milenio de Oceanografía - Chile
Universidad Nacional Andrés Bello - Chile |
| 8 | White, Jessica A. | - |
PATH - Estados Unidos
|
| 9 | Kalergis, Alexis M. | - |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile |
| 10 | BUENO-RAMIREZ, SUSAN MARCELA | Mujer |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile |
| 11 | Gonzalez, Pablo A. | - |
Instituto Milenio de Oceanografía - Chile
Pontificia Universidad Católica de Chile - Chile |
| Fuente |
|---|
| Millennium Institute on Immunology and Immunotherapy |
| Bill & Melinda Gates Foundation |
| Innovation Fund for Competitiveness |
| Ministry of Health, Government of Chile |
| Agencia Nacional de Investigacion y Desarrollo (ANID) |
| Chilean Public Health Institute |
| Confederation of Production and Commerce, Chile |
| Sinovac Life Sciences |
| Millennium Institute on Immunology and Immunotherapy (Iniciativa Cientifica Milenio, ICM) |
| Consortium of Universities for Vaccines and Therapies against COVID-19, Chile |
| Agradecimiento |
|---|
| This work was supported by the Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/ ; grants INV-021239 and INV-016821); the Agencia Nacional de Investigacion y Desarrollo (ANID) (grants N degrees 1190830, N degrees 1170964, and N degrees 1190864 to A. M. K., S. M. B., and P. A. G., respectively, through the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT); fellowship 21221163 to B. D. V. through the National Doctoral Scholarship; and postdoctoral FONDECYT grant N degrees 3210473 to L. F. D.); the Millennium Institute on Immunology and Immunotherapy (Iniciativa Cientifica Milenio, ICM, grant ICN2021_045; former ICN09_016, P09/016-F to A. M. K., S. M. B., and P. A. G.); and the Innovation Fund for Competitiveness (grant FIC-R 2017 [BIP code 30488811-0] to A. M. K., S. M. B., and P. A. G.). Scientific-clinical studies that generated serum samples evaluated in this report (CoronaVac03CL, CoronaVac03CL booster dose, and CoronaVac03CL second booster dose) were supported by the Ministry of Health, Government of Chile; the Confederation of Production and Commerce, Chile; the Consortium of Universities for Vaccines and Therapies against COVID-19, Chile; the Chilean Public Health Institute; the Millennium Institute on Immunology and Immunotherapy; and Sinovac Life Sciences. Funding to pay the Open Access publication charges for this article was provided by the Bill & Melinda Gates Foundation. |